Researchers examined the medical records of 81 cystic fibrosis patients and grouped them into four quartiles based on the dosage of aminoglycoside antibiotics that each patient received.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox
The study shows that the two highest dosage groups were 4.79 times more likely to experience permanent hearing loss than groups receiving the lowest cumulative dosage.
The study notes that, if possible, providers should consider alternative strategies for treating cystic fibrosis-associated respiratory infections.
“This is an early step toward developing a model for predicting hearing loss in these patients,” said lead author Angela Garinis, PhD, a senior research associate in the Oregon Hearing Research Center at Oregon Health & Science University in Portland.
More articles on quality:
8 hospitals in Maryland with top nurse-patient communication scores
Wyoming hospital urged to contact patients after unsterile surgical instrument reports
On the brink: 3 dangers of inadequate surgical instrument reprocessing departments
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.